Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.
Type:
Grant
Filed:
July 17, 2009
Date of Patent:
January 31, 2012
Assignee:
Applied Molecular Evolution, Inc.
Inventors:
Julian Davies, Ying Tang, Jeffry Dean Watkins
Abstract: A method to treat conditions associated with A? peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human A? peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.
Abstract: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.
Type:
Grant
Filed:
March 17, 2009
Date of Patent:
June 28, 2011
Assignee:
Eli Lilly and Company
Inventors:
Andrew Ihor Korytko, Rohn Lee Millican, Jr.
Abstract: Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10?8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.
Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.
Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.
Type:
Grant
Filed:
February 6, 2004
Date of Patent:
August 18, 2009
Assignee:
Applied Molecular Evolution
Inventors:
Julian Davies, Ying Tang, Jeffry Dean Watkins